Dexcom G7 Continuous Glucose Monitoring System Receives Regulatory Clearance from Health Canada – Dexcom (NASDAQ:DXCM)

Dexcom, Inc..’S DXCM next generation Dexcom G7 Continuous Glucose Monitoring System has been approved by health canada, This department functions under the Government of Canada and is responsible for national health policy.

The Dexcom G7 can deliver high or low glucose level warnings with predictive immediate low warnings to help avoid potentially dangerous hypoglycemic events. The company said the regulatory approval gives Canadians access to a technology that reduces hospitalizations and emergency room visits due to hypoglycemia by up to 42%.

Read also: Dexcom Revises 2025 Outlook, Announces New Product for Diabetics

“The Dexcom G7 builds on the innovation that our previous CGM systems have brought to the lives of Canadians,” said Andre Cote, Vice President and General Manager, Dexcom Canada.

Through remote monitoring and reporting capabilities, users can share information with family, loved ones and care teams anytime, anywhere.

While Health Canada has approved, the Dexcom G7 has not yet been made available for purchase. Dexcom G7 is expected to launch in Canada end of 2023,

“With the approval of the Dexcom G7, the latest glucose sensor coming to Canada, patients will have a new, easy-to-start and easy-to-use tool in their diabetes management toolbox,” said Alice Cheng, endocrinologist, Trillium Health Partners, Credit. ” Valley Hospital and St Michael’s Hospital.

Price Action: Last Check Shares of DXCM are trading steady at $127.02 in the premarket session on Wednesday.

Source link

Leave a Comment